RNA binding protein dysregulation across ALS FTD and AD

# Novel Therapeutic Hypotheses for RNA Binding Protein Dysregulation in Neurodegeneration ## 1. Stress Granule Phase Separation Modulators **Target:** G3BP1/2, TIA1, TIAR **Mechanism:** Pharmacological modulation of liquid-liquid phase separation dynamics to prevent pathological stress granule persistence and restore RNA homeostasis. **Description:** Small molecules that enhance stress granule dissolution kinetics could prevent the chronic sequestration of RNA-binding proteins and maintain cytoplasmic RNA processing. This approach targets the biophysical properties of ribonucleoprotein condensates rather than individual proteins. **Supporting Evidence:** Stress granules become persistent in ALS (PMID: 28575658), and G3BP1 mutations affect granule dynamics (PMID: 30867371). Phase separation defects are implicated across ALS/FTD/AD spectrum. **Confidence:** 0.8 ## 2. Mitochondrial RNA Granule Rescue Pathway **Target:** SYNCRIP, HNRNPA2B1, TARDBP **Mechanism:** Restoration of mitochondrial RNA transport and local translation by targeting RBPs that regulate mitochondrial RNA granule trafficking along microtubules. **Description:** Enhancing the transport of RNA granules containing mitochondrial mRNAs could restore local protein synthesis at synapses and axon terminals. This addresses the energy deficit common across neurodegenerative diseases. **Supporting Evidence:** TDP-43 regulates mitochondrial gene expression (PMID: 29769719), and HNRNPA2B1 controls mitochondrial RNA transport (PMID: 31253775). Mitochondrial dysfunction is shared across ALS/FTD/AD. **Confidence:** 0.75 ## 3. R-Loop Resolution Enhancement Therapy **Target:** SETX, FUS, TARDBP, HNRNPK **Mechanism:** Pharmacological enhancement of R-loop resolution machinery to prevent DNA damage and transcriptional stress caused by dysregulated RNA-binding proteins. **Description:** Compounds that boost senataxin activity or recruit additional R-loop helicases could prevent the DNA damage accumulation seen when RBPs form pathological aggregates. This targets a convergent pathway of genomic instability. **Supporting Evidence:** FUS mutations cause R-loop accumulation (PMID: 32678095), TDP-43 loss leads to R-loop formation (PMID: 33692130), and SETX mutations cause ALS4. **Confidence:** 0.7 ## 4. Cryptic Exon Silencing Restoration **Target:** TARDBP, FUS, HNRNPH1, RBFOX1 **Mechanism:** Development of antisense oligonucleotides or small molecules that compensate for loss of RBP-mediated cryptic exon repression in disease-relevant transcripts. **Description:** Targeted restoration of normal splicing patterns by artificially silencing cryptic exons that become included when TDP-43 or FUS function is compromised. This approach uses precision medicine to correct specific splicing defects. **Supporting Evidence:** TDP-43 loss causes cryptic exon inclusion in multiple genes (PMID: 28218735), and cryptic exons trigger nonsense-mediated decay (PMID: 29892072). **Confidence:** 0.85 ## 5. Nucleolar Stress Response Normalization **Target:** HNRNPA1, NPM1, FUS, C9ORF72 **Mechanism:** Restoration of nucleolar function and ribosome biogenesis by targeting the nucleolar stress response triggered by RBP dysfunction. **Description:** Compounds that enhance nucleolar integrity and ribosome assembly could counteract the translational deficits caused by RBP pathology. This addresses the fundamental protein synthesis dysfunction underlying neurodegeneration. **Supporting Evidence:** C9ORF72 expansions disrupt nucleolar function (PMID: 28575680), FUS regulates ribosomal RNA processing (PMID: 21358617), and nucleolar stress is prominent in AD (PMID: 31285255). **Confidence:** 0.65 ## 6. Axonal RNA Transport Reconstitution **Target:** HNRNPA2B1, FUS, TARDBP, STAU1 **Mechanism:** Enhancement of kinesin-mediated axonal RNA transport through stabilization of RNA granule cargo and motor protein interactions. **Description:** Therapeutic restoration of long-distance RNA transport in axons by targeting the RNA granule composition and motor protein coupling defects caused by RBP aggregation. This could restore local protein synthesis at synapses. **Supporting Evidence:** HNRNPA2B1 mutations disrupt axonal transport (PMID: 24931472), TDP-43 affects axonal mRNA localization (PMID: 30745308), and transport defects occur early in ALS. **Confidence:** 0.72 ## 7. Cross-Seeding Prevention Strategy **Target:** TARDBP, FUS, TAU, Aβ oligomers **Mechanism:** Prevention of heterotypic protein aggregation between RNA-binding proteins and classical neurodegenerative disease proteins through selective stabilization of native conformations. **Description:** Small molecules that prevent the cross-seeding interactions between TDP-43/FUS aggregates and tau/amyloid pathology could slow disease progression in mixed pathology cases. This targets the convergent aggregation pathways. **Supporting Evidence:** TDP-43 and tau co-aggregate in FTD (PMID: 30126897), TDP-43 pathology correlates with cognitive decli [...]